Novel alternative to fecal microbiota therapy prevents recurrent CDI in study

A novel oral microbiome-directed therapy called VE303 successfully prevented recurrent Clostridioides difficile infection in adults at high risk for recurrence, researchers found.“C. difficile is a leading nosocomial pathogen, with considerable morbidity and mortality,” JeffreyLSilber, MD, chief medical officer of Vedanta Biosciences, told Healio.“Despite initial improvement with a course of antibiotics, at least 20% of patients with [C. difficile infection (CDI)] suffer a recurrence within a few weeks. Once someone suffers a recurrence, the probability of additionalRead More